The striatal long noncoding RNA Abhd11os is neuroprotective against an N-terminal fragment of mutant huntingtin invivo

Neurobiology of Aging

Volumn 36, Issue 3, 2015, Pages 1601.e7-1601.e16

  Francelle, Laetitia ^a,b   Galvan, Laurie ^a,b   Gaillard, Marie Claude ^a,b   Petit, Fanny ^a,b   Bernay, Benoît ^c,d,e   Guillermier, Martine ^a,b   Bonvento, Gilles ^a,b   Dufour, Noëlle ^a,b   Elalouf, Jean Marc ^c,d,e   Hantraye, Philippe ^a,b   Déglon, Nicole ^a,b   de Chaldée, Michel ^c,d,e   Brouillet, Emmanuel ^a,b  

^a Molecular Imaging Research Center   (France)

^b SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

^c SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^d INSTITUTE FOR INTEGRATIVE BIOLOGY OF THE CELL I2BC   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Gene regulation; Huntington disease; Neurodegeneration; Neuroprotection; Noncoding RNA; Striatum

Indexed keywords

HUNTINGTIN; LENTIVIRUS VECTOR; LONG UNTRANSLATED RNA; LONG UNTRANSLATED RNA ABHD11OS; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ABHD11 PROTEIN, HUMAN; HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NEUROPROTECTIVE AGENT; NUCLEAR PROTEIN; SERINE PROTEINASE; SMALL INTERFERING RNA; UNTRANSLATED RNA;

ADULT; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DISEASE COURSE; DOWN REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IN VIVO STUDY; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CELLS, CULTURED; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; HUNTINGTON DISEASE; MALE; MICE, INBRED C57BL; MUTATION; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; RNA, UNTRANSLATED; SERINE PROTEASES;

EID: 84923568472     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.11.014     Document Type: Article

References (48)

1. Benchoua A., Trioulier Y., Diguet E., Malgorn C., Gaillard M.C., Dufour N., Elalouf J.M., Krajewski S., Hantraye P., Deglon N., Brouillet E. Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum. Mol. Genet. 2008, 17:1446-1456.
2. Bhan A., Mandal S.S. Long noncoding RNAs: emerging stars in gene regulation, epigenetics and human disease. ChemMedChem 2014, 9:1932-1956.
3. Blum D., Hourez R., Galas M.C., Popoli P., Schiffmann S.N. Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol. 2003, 2:366-374.
4. Borrell-Pages M., Zala D., Humbert S., Saudou F. Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol. Life Sci. 2006, 63:2642-2660.
5. Brochier C., Gaillard M.C., Diguet E., Caudy N., Dossat C., Segurens B., Wincker P., Roze E., Caboche J., Hantraye P., Brouillet E., Elalouf J.M., de Chaldee M. Quantitative gene expression profiling of mouse brain regions reveals differential transcripts conserved in human and affected in disease models. Physiol. Genomics 2008, 33:170-179.
6. Brouillet E., Jacquard C., Bizat N., Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J.Neurochem. 2005, 95:1521-1540.
7. Cech T.R., Steitz J.A. The noncoding RNA revolution-trashing old rules to forge new ones. Cell 2014, 157:77-94.
8. Cha J.H. Transcriptional signatures in Huntington's disease. Prog. Neurobiol. 2007, 83:228-248.
9. Charvin D., Vanhoutte P., Pages C., Borrelli E., Caboche J. Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:12218-12223.
10. Chung D.W., Rudnicki D.D., Yu L., Margolis R.L. Anatural antisense transcript at the Huntington's disease repeat locus regulates HTT expression. Hum. Mol. Genet. 2011, 20:3467-3477.
11. Cowan C.M., Raymond L.A. Selective neuronal degeneration in Huntington's disease. Curr. Top Dev. Biol. 2006, 75:25-71.
12. Damiano M., Diguet E., Malgorn C., D'Aurelio M., Galvan L., Petit F., Benhaim L., Guillermier M., Houitte D., Dufour N., Hantraye P., Canals J.M., Alberch J., Delzescaux T., Deglon N., Beal M.F., Brouillet E. Arole of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin. Hum. Mol. Genet. 2013, 22:3869-3882.
13. Damiano M., Galvan L., Deglon N., Brouillet E. Mitochondria in Huntington's disease. Biochim. Biophys. Acta 2010, 1802:52-61.
14. de Almeida L.P., Ross C.A., Zala D., Aebischer P., Deglon N. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J.Neurosci. 2002, 22:3473-3483.
15. Desplats P.A., Kass K.E., Gilmartin T., Stanwood G.D., Woodward E.L., Head S.R., Sutcliffe J.G., Thomas E.A. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J.Neurochem. 2006, 96:743-757.
16. Diguet E., Petit F., Escartin C., Cambon K., Bizat N., Dufour N., Hantraye P., Deglon N., Brouillet E. Normal aging modulates the neurotoxicity of mutant huntingtin. PLoS One 2009, 4:e4637.
17. Drouet V., Perrin V., Hassig R., Dufour N., Auregan G., Alves S., Bonvento G., Brouillet E., Luthi-Carter R., Hantraye P., Deglon N. Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol. 2009, 65:276-285.
18. Faideau M., Kim J., Cormier K., Gilmore R., Welch M., Auregan G., Dufour N., Guillermier M., Brouillet E., Hantraye P., Deglon N., Ferrante R.J., Bonvento G. Invivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum. Mol. Genet. 2010, 19:3053-3067.
19. Galindo M.I., Pueyo J.I., Fouix S., Bishop S.A., Couso J.P. Peptides encoded by short ORFs control development and define a new eukaryotic gene family. PLoS Biol. 2007, 5:e106.
20. Galvan L., Lepejova N., Gaillard M.C., Malgorn C., Guillermier M., Houitte D., Bonvento G., Petit F., Dufour N., Hery P., Gerard M., Elalouf J.M., Deglon N., Brouillet E., de Chaldee M. Capucin does not modify the toxicity of a mutant Huntingtin fragment invivo. Neurobiol. Aging 2012, 33:1845 e1845-1846.
21. Geisler S., Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat. Rev. Mol. Cell. Biol. 2013, 14:699-712.
22. Gray M., Shirasaki D.I., Cepeda C., Andre V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., Li X.J., Levine M.S., Yang X.W. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J.Neurosci. 2008, 28:6182-6195.
23. Harper, P.S. (1991). Huntington's Disease.
24. Heiman M., Schaefer A., Gong S., Peterson J.D., Day M., Ramsey K.E., Suarez-Farinas M., Schwarz C., Stephan D.A., Surmeier D.J., Greengard P., Heintz N. Atranslational profiling approach for the molecular characterization of CNS cell types. Cell 2008, 135:738-748.
25. Hottinger A.F., Azzouz M., Deglon N., Aebischer P., Zurn A.D. Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J.Neurosci. 2000, 20:5587-5593.
26. Johnson R., Teh C.H., Jia H., Vanisri R.R., Pandey T., Lu Z.H., Buckley N.J., Stanton L.W., Lipovich L. Regulation of neural macroRNAs by the transcriptional repressor REST. RNA 2009, 15:85-96.
27. Lai F., Orom U.A., Cesaroni M., Beringer M., Taatjes D.J., Blobel G.A., Shiekhattar R. Activating RNAs associate with mediator to enhance chromatin architecture and transcription. Nature 2013, 494:497-501.
28. Menalled L.B., Sison J.D., Dragatsis I., Zeitlin S., Chesselet M.F. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats. J.Comp. Neurol. 2003, 465:11-26.
29. Mievis S., Blum D., Ledent C. A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. Neurobiol. Dis. 2011, 41:570-576.
30. Perrin V., Dufour N., Raoul C., Hassig R., Brouillet E., Aebischer P., Luthi-Carter R., Deglon N. Implication of the JNK pathway in a rat model of Huntington's disease. Exp. Neurol. 2009, 215:191-200.
31. Perrin V., Regulier E., Abbas-Terki T., Hassig R., Brouillet E., Aebischer P., Luthi-Carter R., Deglon N. Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol. Ther. 2007, 15:903-911.
32. Peschansky V.J., Wahlestedt C. Non-coding RNAs as direct and indirect modulators of epigenetic regulation. Epigenetics 2014, 9:3-12.
33. Roze E., Saudou F., Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr. Opin. Neurol. 2008, 21:497-503.
34. Ruiz M., Deglon N. Viral-mediated overexpression of mutant huntingtin to model HD in various species. Neurobiol. Dis. 2012, 48:202-211.
35. Seredenina T., Gokce O., Luthi-Carter R. Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation. PLoS One 2011, 6:e22231.
36. Seredenina T., Luthi-Carter R. What have we learned from gene expression profiles in Huntington's disease?. Neurobiol. Dis. 2012, 45:83-98.
37. Subramaniam S., Sixt K.M., Barrow R., Snyder S.H. Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Science 2009, 324:1327-1330.
38. Tabrizi S.J., Scahill R.I., Owen G., Durr A., Leavitt B.R., Roos R.A., Borowsky B., Landwehrmeyer B., Frost C., Johnson H., Craufurd D., Reilmann R., Stout J.C., Langbehn D.R., Investigators T.-H. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013, 12:637-649.
39. Tan L., Yu J.T., Hu N., Tan L. Non-coding RNAs in Alzheimer's disease. Mol. Neurobiol. 2013, 47:382-393.
40. Anovel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983. The-Huntington's-Disease-Collaborative-Research-Group.
41. Thomas E.A. Striatal specificity of gene expression dysregulation in Huntington's disease. J.Neurosci. Res. 2006, 84:1151-1164.
42. Ulitsky I., Bartel D.P. lincRNAs: genomics, evolution, and mechanisms. Cell 2013, 154:26-46.
43. Vucicevic D., Schrewe H., Orom U.A. Molecular mechanisms of long ncRNAs in neurological disorders. Front. Genet. 2014, 5:48.
44. Walker F.O. Huntington's disease. Lancet 2007, 369:218-228.
45. Wang K.C., Yang Y.W., Liu B., Sanyal A., Corces-Zimmerman R., Chen Y., Lajoie B.R., Protacio A., Flynn R.A., Gupta R.A., Wysocka J., Lei M., Dekker J., Helms J.A., Chang H.Y. Along noncoding RNA maintains active chromatin to coordinate homeotic gene expression. Nature 2011, 472:120-124.
46. Winslow A.R., Rubinsztein D.C. Autophagy in neurodegeneration and development. Biochim. Biophys. Acta 2008, 1782:723-729.
47. Wu P., Zuo X., Deng H., Liu X., Liu L., Ji A. Roles of long noncoding RNAs in brain development, functional diversification and neurodegenerative diseases. Brain Res. Bull. 2013, 97:69-80.
48. Zuccato C., Cattaneo E. Huntington's disease. Handb. Exp. Pharmacol. 2014, 220:357-409.